Your session is about to expire
← Back to Search
Durvalumab + Tremelimumab for Non-Small Cell Lung Cancer (NEPTUNE Trial)
NEPTUNE Trial Summary
This trial is testing a new combination therapy for patients with advanced lung cancer who have not yet been treated. The new therapy combines two drugs, durvalumab and tremelimumab. The trial will compare this new therapy to standard chemotherapy to see if it is more effective and has fewer side effects.
NEPTUNE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NEPTUNE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't received any treatment for my recurrent or metastatic NSCLC.I have stable brain metastases and haven't taken steroids for 14 days.My lung cancer is a mix of small cell and non-small cell types.I have never received immune therapy for cancer, except for cancer vaccines.I am fully active or able to carry out light work.I am 18 years old or older.I have or had an autoimmune or inflammatory disorder like Crohn's disease.My condition is Stage IV non-small cell lung cancer.My cancer does not have EGFR mutations or ALK rearrangements.
- Group 1: Combination Therapy
- Group 2: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the usual indications for Durvalumab +Tremelimumab?
"Durvalumab and Tremelimumab can be used to treat cancer in the fallopian tubes, diseases, and advance directives."
Are there multiple sites where I can enroll in this research project?
"Currently, this trial is running at 15 sites. These include locations in Columbus, Houston and Anaheim. To minimize travel burdens, try to select the location nearest you."
Are patients over the age of 70 eligible for this research study?
"In order to be eligible for this specific study, patients must between 18-130 years old. There are a total of 140 studies currently taking place for patients that are under 18 and 3404 studies available for those over 65."
Are there any qualifiers for participants in this trial?
"This study is for patients that have non-small cell lung carcinoma (NSCLC) and are between 18 to 130 years old. In total, 953 people can be enrolled in the trial."
Are there other ongoing research studies testing the combination of Durvalumab +Tremelimumab?
"City of Hope Comprehensive Cancer Center published the first study on Durvalumab +Tremelimumab in 1997 and, since then, there have been 2760 completed trials. Out of these, 1922 are active studies; a great many of which are based in Columbus, Ohio."
Share this study with friends
Copy Link
Messenger